Details
Description
The risk of severe uterine bleeding (SUB) reported in oral anticoagulant (OA) clinical trials is likely underestimated due to the low representation of women of reproductive age. In a previous research letter, we reported SUB incidence in women who received OA treatment using real-world data. In this study, we examined the incidence of SUB among women presenting uterine bleeding (UB), with and without ongoing OA (warfarin or non-vitamin K oral anticoagulants) exposure, to contextualize our previous findings.